Ressources

We identified longitudinal substance use profiles in young Black American men and examined their links to childhood adversity, racial discrimination and young adult problem substance use and mental

Gender and sexual minority/minoritized groups are at a higher risk of substance misuse and related harm compared to the rest of the population.

We assessed the prevalence and risk of mortality for concurrent alcohol use disorder (AUD) among people with opioid use disorder (PWOUD) who accessed opioid agonist therapy (OAT) in British Columbi

This paper analyses a translation of an Italian Renaissance Latin monograph’s key content elements and its place in the history of the concept of addiction.

Given the widespread presence of fentanyl in the drug supply, research is needed to understand who is at greatest risk for concurrent medication for opioid use disorder (MOUD) and drug use and the

Here, we examined the neuropharmacology of structurally distinct non-fentanyl NSOs, including U-47700, isotonitazene, brorphine, and N-desethyl isotonitazene, as compared to morphine and fentanyl.

We examine if the shift to the illicit market after the reformulation of OxyContin in the U.S.

This cross-sectional study investigates the impact of benzodiazepine (BZD) use in opioid agonist treatment (OAT) patients on their quality of life (QoL).

We conducted a rapid review of qualitative and quantitative peer-reviewed and grey literature publications that describe the clinical outcomes of SOS programs, as well as the perceptions of clients

We investigated the association between fentanyl injection frequency and sharing of injection equipment among people who inject drugs

We measured the prevalence of mono-use versus polysubstance use (PSU) in those who used substances in the past year, those with at least two symptoms of an SUD and in those who received treatment f

We sought to examine linkages between socioeconomic marginalization and non-fatal overdose risk in a community deeply affected by the ongoing drug poisoning crisis.

We sought to describe longitudinal trends in buprenorphine receipt and buprenorphine-waivered providers in the United States from 2003 to 2021 and measure whether the relationship between the two d